Asian healthcare-focused private equity firm Quadria Capital is considering selling its minority stake in Indian topical pharmaceutical company Encube Ethicals Pvt, people familiar with the matter said https://t.co/typwsQAk7F ...

Entrepreneurial Journey & Mindset - The speaker emphasizes the importance of taking the first step in pursuing one's goals, even when faced with doubt or uncertainty [1][2][6][7] - The speaker highlights the transition from a corporate job at Bank of America to renewable energy and LED lighting, driven by a desire to make a real impact [2] - The speaker shares experiences of failure and learning in the solar energy sector, emphasizing perseverance and continuous effort [3][4] - The speaker advocates for acting with courage, building with intent, and committing with belief (the ABC formula) as key principles for success [6][7] Business Ventures & Achievements - The speaker successfully exited a solar energy company after initial struggles [4] - The speaker scaled a pharmaceutical company from 100 crores (approximately $12 million USD, conversion based on current exchange rates) before a fire accident [4] - The speaker built a virtual pharmaceutical company without owning a factory, projected to reach nearly $100 million USD in sales by 2025 [4] - The speaker represented India in 25 international badminton tournaments, highlighting the belief in oneself and the ability to create a global company [5][6] Key Takeaway - The speaker encourages the audience to seize opportunities and take action now, emphasizing the importance of "just in time" rather than "just in case" [7][8]

Pharmaceutical Industry Trends & Future Directions - The pharmaceutical field is dynamic, with innovations like hydrogels for prolonged drug effects and biodegradable implants for long-term drug delivery [20] - Micro needles, similar to nicotine patches, offer a less invasive drug delivery method [21] - Personalized medicine, driven by AI, is an upcoming trend, tailoring therapies based on individual genetic codes [21] - Nanoparticles are being explored for targeted cancer treatment, aiming for better therapeuticity and reduced harm to normal cells [19] - Lipid nanoparticles are crucial for mRNA vaccines, delivering RNA to help the body battle diseases [17] Drug Development & Treatment Advancements - The development of anti-retroviral therapy (ART) for the first pandemic (likely referring to HIV/AIDS) took 15 years [16] - The development of mRNA vaccines for the COVID-19 pandemic took less than a year [16] - Nanoparticles can be functionalized in various shapes to reach inaccessible parts of the body, potentially revolutionizing medicine [18] Personal Journey & Passion in Pharmaceutics - Passion is defined as being fascinated by something to the point of losing track of time [3] - The speaker's initial plan was not pharmaceutics, but a desire to help people and save lives, influenced by family experiences with breast cancer, led to this path [5][6] - The speaker shifted from wanting to be in corporate to wanting to be in the lab, focusing on the scientific aspects of drug creation [8] - Pursuing a master's in the US was chosen due to better funding and infrastructure compared to India [9]

Company Overview - A company with Donald Trump Jr on its board launched a new service [1] Industry Focus - The new service assists pharmaceutical companies in launching direct sales platforms [1] Political Context - The launch occurred one week after President Donald Trump urged drugmakers to establish similar systems [1]

Drug Development & Clinical Trials - Eli Lilly's oral weight loss drug trial results met internal expectations, despite market disappointment, with an average weight loss of 27 pounds [2][3] - The company plans to submit the oral weight loss drug to regulators by the end of the year, anticipating potential approvals around the same time next year [4] - Safety risks associated with orforglipron have been largely addressed, paving the way for its potential as a mass-market obesity treatment [8][9] - Dropout rates in the study were comparable to placebo, alleviating concerns about the drug's tolerability [12][16] - Seven phase three studies are underway for the medicine [14] Market Position & Financial Performance - The pharmaceutical sector's price-to-earnings multiples have compressed in the last year, affecting stock prices across the industry [6] - Eli Lilly's sales increased by 38% year-over-year in the second quarter [7] - Tirzepatide (Mounjaro and Zepbound) is projected to become the best-selling drug in the industry within its third year on the market [7] - The company emphasizes its focus on increasing value for patients and investors [7] Obesity Market & Treatment Landscape - The current obesity treatment market only addresses approximately 2-3% of the global population [9] - There are an estimated 1 billion people worldwide who are overweight or obese, highlighting the significant market potential for effective treatments [9]

Not for distribution to United States newswire services or for dissemination in the United States VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) -- EnWave Corporation (TSX- V:ENW | FSE:E4U) ("EnWave", or the "Company") is pleased to announce that it has entered into an agreement with Clarus Securities Inc. ("Clarus"), as lead agent and sole bookrunner, pursuant to which Clarus has agreed to sell, on a "best efforts" private placement basis, up to 7,500,000 common shares of the Company (the "Sha ...

Company Performance - Eli Liy's market capitalization has increased by approximately 860% since the current CEO took office [1] - The stock price is up a little bit more than 1,000% [1] Drug Development & Market - Eli Liy is the world's most valuable pharmaceutical company and a leader in the GLP-1 drug market [1] - GLP-1 drugs have become increasingly popular [1] - Eli Liy says it has a pill, eliminating the need for needles [1] - Eli Lily's experimental pill appears to work as well as the injected drug [2]

Financial Performance & Cost Reduction - Pfizer reported exceeding its initial cost reduction program for the year and announced an additional 17 billion USD cost reduction plan, with 12 billion USD impacting administrative, marketing, and selling expenses by 2027, and 500 million USD reinvested in R&D [3] - Pfizer experienced 10% revenue growth this quarter, but revenue growth has been volatile due to the fluctuating impact of COVID-19 [3][4] - New products and recently acquired products contributed 47 billion USD in the first half of the year, growing at 15% [5] Operational Strategy - Pfizer is focusing on productivity enhancement and margin expansion through focus on key priorities and leveraging technology, particularly AI, to simplify business processes and reduce waste [1][2] - Pfizer aims to streamline operations by eliminating less important activities and concentrating on core strengths [2] Regulatory & Political Landscape - The CEO of Pfizer has a special relationship with the US President, particularly stemming from collaboration during the COVID-19 crisis, and has discussed the impact of middlemen on drug prices [8][9] - The US President aims to secure better deals on drug pricing, expressing concern that other countries pay less [10] - The US President is considering tariffs, potentially reaching 250%, on imports, but may phase them in and allow a grace period due to the long lead times required for pharmaceutical manufacturing site completion (over 4 years) [11][12][13] - The pharmaceutical industry is engaging in discussions with the US President regarding the "most favored nations" pricing clause and potential mitigation plans [17] - Generics account for over 90% of prescriptions in the US and are the cheapest globally, but patients may still pay more due to the insurance system [19][20] - Pfizer has a significant manufacturing presence in the US, with 13 sites, including 11 manufacturing plants [20] - The impact of tariffs depends on the product and how customs authorities define the country of origin, considering both API origin and final product location [19][21]

Financial Data and Key Metrics Changes - Net Asset Value (NAV) increased by $252 million from the first quarter, primarily driven by positive performance in CVI, offset by decreases in auto service [5] - The investment funds ended down approximately 0.5% for the quarter, primarily driven by gains in the consumer cyclical sector, offset by broad market and refining hedges [6] - The holding company ended the quarter with $1.1 billion in cash and cash equivalents, and an additional $700 million of cash at the funds [10] Business Line Data and Key Metrics Changes - Energy segment consolidated EBITDA was negative $24 million for Q2 2025 compared to $103 million in Q2 2024, negatively impacted by unfavorable RINs valuation and reduced throughput volumes [14] - Automotive service revenues decreased by $8 million compared to the prior year quarter, but same-store revenues improved from a 5% decline to 1% growth in May and June [15] - Real estate's Q2 2025 adjusted EBITDA decreased by $2 million compared to the prior year quarter, following the sale of a successful country club investment [17] - Food packaging's adjusted EBITDA decreased by $9 million for Q2 2025 due to lower volume and higher manufacturing inefficiencies [18] Market Data and Key Metrics Changes - CVI's share price increased by 38%, contributing to a $561 million increase in NAV from the first quarter [5] - The auto service division showed a positive trajectory in revenue growth, indicating a potential turnaround [15] Company Strategy and Development Direction - The company is focusing on maintaining liquidity to capitalize on opportunities within and outside existing operating segments, with a total liquidity of $3.5 billion at the holding company and $1.1 billion at subsidiaries [19] - The company plans to redeploy capital from the successful country club sale to new opportunities, aiming to replicate past successes [17] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism regarding the resolution of outstanding litigation related to small refinery exemptions, which could remove a $548 million liability [6] - The company sees considerable value creation potential in its portfolio, particularly in electric utilities and digital businesses [11][12] Other Important Information - CVI's CEO, Dave Lamp, will retire at year-end, with Mark Pytosh being promoted as his replacement [6] - The Board maintained the quarterly distribution at $0.50 per depositary unit [10] Q&A Session Summary Question: Regarding the decrease in cash balance at the holding company level - The decrease was primarily due to interest payments and LP distributions, with some impact from the CVR repurchase of about $32 million [21]

According to recent data, the prices that Americans have been paying for brandame drugs are more than three times the price other similar similarly developed nations pay. The president is determined to solve this problem and took further action today. He has signed 17 letters to pharmaceutical companies CEOs and I would like to read you one of these letters to the CEO of Eli Liy.On May 12th, 2025, I signed an executive order delivering most favored nation prescription drug pricing to American patients to st ...